Veradigm Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Veradigm Inc (MDRX) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Veradigm Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 593M vs 661,192M combined for tracked competitors (0.1% combined share).
- Trending: Latest-quarter revenue run-rate is holding steady (+0.3% annualized vs trailing 12 months), vs decelerating (-3.1%) for its tracked peer group.
- Growth: Veradigm Inc generated -3.7% revenue growth year over year in Q4 2024, vs 4.3% for its tracked competitors combined.
- Profitability: Its -178.1% net margin compares with 2.6% for the peer group.
- Scale: Veradigm Inc ranks #69 of 165 companies by market capitalization in the Cloud Computing & Data Analytics industry, holding 0.1% of industry market cap.
- Peer revenue share: Veradigm Inc accounted for 0.1% of combined revenue among its tracked peer group, down from 0.1% a year earlier.
- Peer differentiation: Revenue per employee of $0.07M compares with $0.53M for the peer group (0.1x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
MDRX Sales vs. its Competitors, Q4 2024
Veradigm Inc reported revenue contraction of 3.72 % year on year in Q4 2024, below its competitors' combined revenue growth of 4.29 %.
With a net margin of -178.11 %, Veradigm Inc reported lower profitability than its competitors (2.60 %).
Veradigm Inc generated 0.09 % of the combined sales of its peer group, down from 0.10 % a year earlier.
Veradigm Inc vs. its Competitors, Q4 2024
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Veradigm Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Veradigm Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (2) | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (10) | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (4) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Veradigm Inc's competitor groups requires a Commercial License.
For context: the Cloud Computing & Data Analytics industry grew revenue 1.3% year over year, combined, vs -3.7% for Veradigm Inc. Veradigm Inc's share of combined industry revenue moved from 0.11% to 0.11%, a loss of 0.01 percentage points.
Veradigm Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Veradigm Inc | No | No | No | Yes |
| Competitors combined (21) | ||||
| High-Confidence Competitors (4) | ||||
| Similar-Size Competitors (10) | ||||
| Similar Growth & Profitability (8) | 0.00 % (0 of 7) | 62.50 % (5 of 8) | 50.00 % (4 of 8) | 42.90 % (3 of 7) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
MDRX Stock Performance relative to its Competitors
MDRX Stock Performance relative to High-Confidence Competitors
MDRX Stock Performance relative to Similar-Size Competitors
MDRX Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Onemednet Corporation | 282.9% | Outperformed |
| 2 | Premier Inc | 282.9% | Outperformed |
| 3 | Nrc Health | 282.9% | Outperformed |
| 4 | Aspen Technology inc | 282.9% | Outperformed |
| 5 | Teradata Corporation | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Veradigm Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Veradigm Inc's Comment on Competition and Industry Peers
Additionally, many of our prospective clients have invested substantial personnel and financial resources to implement and integrate competing solutions to ours. As a consequence, they may be reluctant or unwilling to migrate to our solutions. Third-party developers may be reluctant to build application services on our platform since they have invested in other competing technology platforms.
We compete primarily with numerous types of organizations, including developers of revenue cycle and practice management software and services, large system integrators, IT service providers, ambulatory and acute care EHR solutions, population health management and value-based care technologies, analytics systems, care management solutions and post-acute solutions. We generally compete on the basis of several factors, including breadth and depth of services (including our open architecture and the level of solution integration across care settings), integrated platform, regulatory compliance, reputation, reliability, accuracy, security, client service, total cost of ownership, innovation and industry acceptance, expertise and experience.
Moreover, we expect that competition will continue to increase as a result of consolidation in both the IT and healthcare industries. If one or more of our competitors or potential competitors were to merge or partner with another of our competitors, the change in the competitive landscape could adversely affect our ability to compete effectively.
Our principal existing competitors in these markets include, but are not limited to (in alphabetical order) AdvancedMD, athenahealth Inc., Cerner Corporation, Change Healthcare, CPSI (Computer Programs and Systems Inc.), CureMD Healthcare, eClinicalWorks, Enli Health Intelligence, Epic Systems Corporation, Evolent Health, GE Healthcare, Greenway Medical Technologies, Harris Healthcare, Healthagen, Health Catalyst, Homecare Homebase (part of Hearst Health network), IBM Watson Health, IQVIA, Kareo, MEDHOST, Inc., Meditech (Medical Information Technology, Inc.), Navicure/Zirmed, NaviHealth (a Cardinal Health company), nThrive, Optum, Philips Wellcentive, Premier Inc., Quadramed, Quality Systems, Inc., Roper Industries, T-System, The TriZetto Group, Inc. (a division of Cognizant Technology Solutions, Inc.) and Wellsoft Corporation.
Publicly Traded Peers of Veradigm Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Veradigm Inc | 508.42 | 593.11 |
| International Business Machines Corporation | 210,118.35 | 69,096.00 |
| Cvs Health Corporation | 112,265.01 | 415,086.00 |
| Infosys Limited | 43,322.94 | 20,158.00 |
| Aspen Technology inc | 16,821.43 | 1,140.15 |
| Walgreens Boots Alliance Inc | 10,361.50 | 154,579.00 |
| SUBTOTAL | 416,530.53 | 705,845.93 |
Sign in to see all competitors of Veradigm Inc .
Sources: Veradigm Inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Veradigm Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Veradigm Inc's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Cerner Corporation | Named by the company | 85% |
| Roper Industries | Named by the company | 85% |
| Premier Inc | Named by the company | 85% |
| Wellsoft Corporation | Named by the company | 85% |
| Epic Systems Corporation | Named by the company | 85% |
| The TriZetto Group | Named by the company | 85% |
| Quality Systems | Named by the company | 85% |
| Greenway Medical Technologies | Named by the company | 85% |
| Medical Information Technology | Named by the company | 85% |
| Cognizant Technology Solutions | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Veradigm Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Veradigm Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Veradigm Inc | Provider 79.61 % |
| International Business Machines Corporation | Software 45.22 % |
| Cvs Health Corporation | Health Services 48.03 % |
| Walgreens Boots Alliance Inc | United States Retail Pharmacy 78.78 % |
| Premier Inc | Supply Chain Services 63.48 % |
| Kyndryl Holdings Inc | Principal Markets Segment 35.77 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Veradigm Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Veradigm Inc | 508 | 66,642 | -49,764 |
| International Business Machines Corporation | 210,118 | 226,322 | 35,129 |
| Cvs Health Corporation | 112,265 | 1,383,620 | 16,283 |
| Infosys Limited | 43,323 | 77,645 | 12,773 |
| Aspen Technology inc | 16,821 | 1,301,540 | 6,999 |
| Walgreens Boots Alliance Inc | 10,362 | 495,446 | -25,365 |
| PEERS TOTAL | 416,022 | 527,483 | 7,576 |
Veradigm Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Veradigm Inc | US 99.91 % |
| International Business Machines Corporation | Americas 49.04 % |
| Aspen Technology inc | Americas 55.75 % |
| Bentley Systems Incorporated | United States, Canada, and Latin America 53.29 % |
| Kyndryl Holdings Inc | Countries Excluding United States and Japan 59.79 % |
| Willdan Group inc | US 100.00 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Veradigm Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 148 companies in Veradigm Inc's industry classification, broader than the peer set above. Market cap in millions of $.Veradigm Inc ranks #69 of 148 companies by market capitalization in its industry, holding 0.09 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 547, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Automatic Data Processing Inc | 104,826 | 16.88 % |
| 2 | Workday Inc | 45,825 | 7.38 % |
| 3 | Infosys Limited | 43,323 | 6.98 % |
| 4 | Zscaler Inc | 31,614 | 5.09 % |
| 5 | Reddit Inc | 1,234 | 5.2% |
| 6 | Cognizant Technology Solutions Corporation | 1,234 | 5.2% |
| 7 | Verisign Inc | 1,234 | 5.2% |
| 8 | Verisk Analytics Inc | 1,234 | 5.2% |
| 9 | Toast Inc | 1,234 | 5.2% |
| 10 | Wipro Limited | 1,234 | 5.2% |
| 69 | Veradigm Inc | 546 | 0.09 % |
Market cap and industry share for the rest of Veradigm Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-09-28.
Veradigm Inc's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 64 | Yext Inc | 656 | -26.64 % |
| 65 | Ooma Inc | 614 | 70.27 % |
| 66 | Cars com Inc | 593 | -14.46 % |
| 67 | Sophia Genetics Sa | 568 | 104.24 % |
| 68 | Nerdwallet Inc | 1,234 | 12.3% |
| 69 | Veradigm Inc | 546 | - |
| 70 | Gravity co ltd | 1,234 | 12.3% |
| 71 | Spectral Capital Corporation | 1,234 | 12.3% |
| 72 | Kodiak Ai Inc | 1,234 | 12.3% |
| 73 | Ci and t Inc | 1,234 | 12.3% |
| 74 | Gloo Holdings Inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Veradigm Inc's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-09-29. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Veradigm Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Cloud Computing & Data Analytics industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (203 companies). See the full Cloud Computing & Data Analytics industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 50.96 % | 51.85 % (avg) | -0.9 pp |
| Operating Margin | -68.14 % | industry median | -66.7 pp |
| EBITDA Margin | 7.87 % | 2.97 % (avg) | +4.9 pp |
| Capital Intensity (Capex / Revenue) | 5.09 % | 5.21 % (avg) | -0.1 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Veradigm Inc's Valuation vs Competitive Position
Valuation multiples vs the Cloud Computing & Data Analytics industry average (203 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Cloud Computing & Data Analytics industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 27.6x | - |
| EV / EBITDA | 20.3x | 16.4x | +3.9x |
| P/B | 1.2x | 4.0x | -2.8x |
| Return on Equity | -49.29 % | industry aggregate | -56.86 % |
| Return on Invested Capital | -21.56 % | 1.95 % (avg) | -23.51 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Veradigm Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | 16.55 % | -3.12 % | 1.24 % | -15.18 % | 0.02 % | -60.92 % | 6.56 % | -5.25 % |
| Operating Margin | 2.32 % | -5.32 % | -1.38 % | -8.71 % | 5.14 % | 2.85 % | 5.54 % | -68.14 % |
| Return on Invested Capital | 0.98 % | -2.11 % | -0.84 % | -3.68 % | 2.45 % | 0.62 % | 1.63 % | -21.56 % |
| P/E | - | 4.9x | - | - | 35.5x | - | 26.2x | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Veradigm Inc's Strategic Group Map
Every company in Veradigm Inc's industry and named-competitor list, plotted by trailing 12-month revenue growth and operating margin. Veradigm Inc is shown in red; its closest peers by combined growth, margin and ROIC (the Similar Growth & Profitability group above) are labeled.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Veradigm Inc's BCG Growth-Share Matrix
Relative market share (vs Veradigm Inc's largest competitor by market cap) against industry revenue growth, using the standard textbook thresholds (1.0x share, 10% growth) a common framework, not a precision instrument.
Veradigm Inc falls in the Dog quadrant: relative market share of 0.01x vs its largest competitor, in an industry growing revenue 5.4% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Veradigm Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 547 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | Moderate, in line with the industry | Capital intensity (capex / revenue) of 5.09 % vs industry average 5.21 % (see Profitability & Cost Structure above) |
| Supplier Power | Not covered on this page | See Veradigm Inc's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Veradigm Inc's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Veradigm Inc's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Veradigm Inc falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Veradigm Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Operating margin 66.7 points below the industry median.
- Return on equity 56.9 points below the industry aggregate.
- Low relative market share vs the industry leader (0.01x).
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
No rule matched.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-3.1% annualized).
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Veradigm Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Veradigm Inc | 0.72 | 1.30 | 0.25 |
| International Business Machines Corporation | 0.29 | 0.87 | 3.47 |
| Cvs Health Corporation | 0.11 | 0.85 | 0.83 |
| Infosys Limited | 0.42 | 1.98 | 0.03 |
| Aspen Technology inc | 0.67 | 2.79 | - |
| Walgreens Boots Alliance Inc | 0.03 | 0.63 | 0.88 |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Veradigm Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Veradigm Inc | Q4 2024 | -3.7 % | - |
| International Business Machines Corporation | Q2 2026 | +1.1 % | -1.3 % |
| Cvs Health Corporation | Q2 2026 | +7.3 % | +195.7 % |
| Infosys Limited | Q1 2026 | +4.6 % | +4.9 % |
| Aspen Technology inc | Q4 2024 | +18.4 % | - |
| Walgreens Boots Alliance Inc | Q2 2025 | +7.2 % | - |
| PEERS TOTAL | +5.8 % | +10.0 % |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Veradigm Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Veradigm Inc | Q4 2024 | -8.7 % | -1.9 % |
| International Business Machines Corporation | Q2 2026 | +3.6 % | +9.0 % |
| Cvs Health Corporation | Q2 2026 | +9.0 % | +13.8 % |
| Infosys Limited | Q1 2026 | +4.4 % | - |
| Aspen Technology inc | Q4 2024 | +0.0 % | +122.2 % |
| Walgreens Boots Alliance Inc | Q2 2025 | +8.7 % | -10.5 % |
Veradigm Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Veradigm Inc | - | - | - |
| International Business Machines Corporation | 7.07% | 7.03% | 33.43% |
| Cvs Health Corporation | 1.92% | 2.81% | 6.39% |
| Infosys Limited | 20.16% | 30.31% | 33.70% |
| Aspen Technology inc | 0.04% | 0.04% | 0.05% |
| Walgreens Boots Alliance Inc | - | - | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Veradigm Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Veradigm Inc | - | 0.86 |
| International Business Machines Corporation | 19.52 | 3.04 |
| Cvs Health Corporation | 22.96 | 0.27 |
| Infosys Limited | 13.84 | 2.15 |
| Aspen Technology inc | 3,304.12 | 14.75 |
| Walgreens Boots Alliance Inc | - | 0.07 |
| PEERS AVERAGE | 43.00 | 0.59 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.